Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use.

ABSTRACT:

Background

Studies have shown the efficacy of asthma biologics in real-world settings, confirming the generalizability of randomized controlled trial (RCT) results, but studies on more than one biologic are scarce. Accordingly, little is known about the different background characteristics in users of asthma biologics. This study aimed to describe the backgrounds of asthma patients using biologics (omalizumab, mepolizumab, benralizumab, and dupilumab) and examine the effectiveness of these biologics for reducing asthma exacerbations and total systemic corticosteroid doses.

Methods

We conducted a retrospective cohort study using self-controlled methods to evaluate the association between the use of biologics and reduction in exacerbations and hospitalizations using a large-sc

SUBMITTER: Kimura Y 

PROVIDER: S-EPMC8585664 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature